ANeuroTech To Launch Pivotal Program With New Dose Of Old Antidepressant
Pipamperone Promise In MDD
Executive Summary
The Belgian firm has the go-ahead from the US FDA for an advanced depression program for ANT-01 including the endpoint of improvement in cognitive function, which could differentiate its label.